Skip to content
AnalystLens

Corteva, Inc. 8-K Report, Financial Results (Jan 31, 2024)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed January 31, 2024
Period End
January 31, 2024
Security
CTVA
In the record · 2019–202610-K710-Q238-K85

CTVA filed 7 annual reports (10-K), 23 quarterly reports (10-Q) and 85 current reports (8-K) between 2019 and 2026.

  1. Change in control8-K · Jun ’19Jun ’19
  2. Leadership change8-K · Feb ’21Feb ’21
  3. Restructuring8-K · Aug ’22Aug ’22
  4. Leadership change8-K · Oct ’26Oct ’26

01—Abstract

Summary

Summary of the 8-K filed January 31, 2024. Cited figures are marked; the original filing is the authoritative source.

Corteva's 4Q and full-year 2023 earnings release (8-K filed January 31, 2024) showed a mixed year.

Full-year net sales fell 1% to $17.23Ba (organic sales down 3%), but Seed grew 5% on price strength (+13%) while Crop Protection fell 9% (organic -12%) amid strategic product exits, channel destocking, and delayed farmer purchases. Fourth-quarter results were weaker: net sales declined 3% to $3.71B, GAAP loss from continuing operations was $(231)M, and GAAP EPS was $(0.33), largely driven by a $241M restructuring charge tied to the Crop Protection network optimization program. Operating EBITDA was $3.38B for the year (+5%), and Operating EPS was $2.69 (+1%), though GAAP EPS from continuing operations fell 22% to $1.30.

Management guided 2024 net sales to $17.4Bb-$17.7B (about 2% growth at midpoint), Operating EBITDA to $3.5B-$3.7B (about 6% growth), and Operating EPS to $2.70-$2.90. Free cash flow is expected to be $1.5B-$2.0B, and the company plans roughly $1.0B in share repurchases. Management expects the Crop Protection industry to modestly improve as channel inventory rebalances, and it anticipates $180M-$230M in net pre-tax restructuring charges in 2024.

For investors, the key takeaways are the strength of pricing and Seed profitability, offset by Crop Protection volume weakness and Latin American headwinds, along with elevated GAAP charges and higher interest expense. Free cash flow improved sharply to $1.2Bc from $307M, supporting the capital return plans. The 2024 guidance implies modest top-line growth with margin expansion, but execution on the Crop Protection turnaround and restructuring will be critical.

02—Key points

Key Highlights

  1. Full-year 2023 net sales declined 1% to $17.23B; organic sales fell 3%, with Seed up 5% (price +13%) and Crop Protection down 9% (volume -14%).
  2. Operating EBITDA rose 5% to $3.38B, and Operating EPS rose 1% to $2.69, while GAAP EPS from continuing operations fell 22% to $1.30.
  3. Q4 2023 GAAP loss from continuing operations of $(231)M, or $(0.33) per share, driven by a $241M restructuring and asset-related charge tied to the Crop Protection operations restructuring program.
  4. Free cash flow more than tripled to $1.21B from $307M, as operating cash flow from continuing operations rose 98% to $1.81B.
  5. 2024 guidance: net sales of $17.4B-$17.7B, Operating EBITDA of $3.5B-$3.7B, and Operating EPS of $2.70-$2.90, implying roughly 6% EBITDA growth at the midpoint.
  6. Planned share repurchases of approximately $1.0B in 2024, following $756M repurchased in 2023.
  7. Interest expense rose sharply to $233M in 2023 from $79M in 2022, reflecting higher debt after $3.4B in debt proceeds and the Stoller and Symborg acquisitions, and is expected to weigh on 2024 EPS.

03—Questions

Frequently Asked Questions

  1. Why did GAAP earnings fall so sharply in Q4 2023 when Operating EBITDA grew?

    GAAP loss from continuing operations was $(231)M in Q4 2023, driven primarily by a $241M restructuring and asset-related charge, largely for the Crop Protection Operations Strategy Restructuring Program. Operating EBITDA excludes these significant items, along with depreciation, interest, exchange losses, and non-operating costs, so it grew 4% to $386M even as GAAP results deteriorated.

  2. What is driving the divergence between Seed and Crop Protection performance?

    Seed benefited from strong pricing (up 13% for the year) and reduced royalty expense, with Seed Operating EBITDA up 28% to $2.1B. Crop Protection faced a 14% volume decline from strategic product exits, channel destocking, and delayed farmer purchases, mainly in Latin America, and its Operating EBITDA fell 18% to $1.37B.

  3. What do the 2024 guidance and restructuring charges mean for investors?

    Guidance calls for modest growth in net sales (about 2% at midpoint) and Operating EBITDA (about 6%), with Operating EPS of $2.70-$2.90. Investors should note that Corteva expects $180M-$230M in net pre-tax restructuring charges in 2024 as it optimizes its Crop Protection manufacturing network, so GAAP earnings may remain well below Operating EPS.

  4. How strong is Corteva's cash generation and capital return capacity?

    Operating cash flow from continuing operations rose to $1.81B in 2023, and free cash flow reached $1.21B after $595M in capital expenditures. The company expects 2024 free cash flow of $1.5B-$2.0B and plans to repurchase about $1.0B of shares, though rising debt and interest expense ($233M in 2023 versus $79M in 2022) are a factor to monitor.

04—Continue

← View all 8-K filings